In a recent study presented at the annual meeting of the International Gynecologic Cancer Society, the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) has shown promising response rates in heavily pretreated patients with HER2-expressing gynecologic cancers.
Dr. Ritu Salani from the University of California Los Angeles highlights the significance of trastuzumab deruxtecan in the field of oncology. This antibody-drug conjugate, which has already demonstrated remarkable efficacy in breast cancer, was now being tested in gynecologic cancers including cervix cancer, ovarian cancer, and endometrial cancer.
The study focused on patients with all levels of HER2 expression, with particular emphasis on those with an immunohistochemistry (IHC) score of 3+ and 2+. Despite being heavily pretreated, these patients exhibited response rates that were unprecedented. The findings showed that trastuzumab deruxtecan holds great promise in the treatment of gynecologic malignancies.
Dr. Salani believes that trastuzumab deruxtecan has the potential to transform the field of gynecologic oncology. While the study is small and further research is needed to understand the patients’ previous treatments and their overall health status, the impressive response rates observed in HER2 expression-positive patients, regardless of IHC score, are truly groundbreaking.
Trastuzumab deruxtecan has already revolutionized practice in other areas of oncology, and experts anticipate that it will soon have a similar impact in gynecologic malignancies. With its broad range of efficacy across different types of cancers, there is hope that this antibody-drug conjugate will receive disease site-agnostic approval or biomarker approval in the future.
As more research is conducted on trastuzumab deruxtecan, the medical community eagerly awaits its potential approval in gynecologic cancers. The encouraging response rates observed in heavily pretreated patients provide a glimmer of hope for those who have exhausted conventional treatment options.
Trastuzumab deruxtecan demonstrates immense promise in the realm of gynecologic oncology. With its remarkable response rates and potential to change the landscape of treatment in heavily pretreated patients with HER2-expressing gynecologic cancers, this antibody-drug conjugate is a beacon of hope for the future of cancer care. As further studies and trials are conducted, it is expected that trastuzumab deruxtecan will pave the way for a new era in personalized and targeted therapies.